

## Seeking Novel Therapeutics with Utility in CNS and PNS Indications



A publicly traded, fully integrated mid-cap biopharmaceutical company with commercial products providing aggregate >\$1B annual revenue is seeking **therapeutic candidates for use in CNS and PNS diseases**. Novel therapeutics should be a **new chemical entity**, ideally with a **composition of matter patent filed** in the last 5 years or with **potential to file a composition of matter patent or other similarly meaningful patent protection**. Our client is a conscientious company looking to bring assets in house and develop them to their full potential.

### Approaches of Interest:

- Open to a range of **neurological and psychiatric** diseases
- For neurodegenerative diseases, **non-disease modifying therapeutics** and treatments for **management of neuropsychiatric symptoms** (e.g. agitation/aggression, apathy, fatigue, psychosis) are also in scope
- Modalities of interest include **small molecules** and **peptides**. Biologics and RNA-based therapies developed by biopharma companies are also of interest
- Potential **first-in-class therapeutics** will be prioritized, potential **best-in-class therapeutics** will also be considered if strong rationale is provided

### Out of Scope:

- Therapeutics with disease-modifying action in neurodegenerative diseases or use in the following indications: nociceptive pain, MS, indications related to acute insult or injury (e.g. stroke, TBI), therapeutics with exclusive use in nicotine use disorder/ smoking cessation, diseases with less than 10,000 US patients
- Repurposed/reformulated therapeutics
- Diagnostics and medical devices
- Digital therapeutics

### Developmental Stages of Interest:

- Opportunities that have a nominated drug candidate through to completion of Phase 1 are of interest, therapeutics that have at least *in vivo* validation are highest priority

### Submission Information

Submission of one-page, 200–300-word briefs is encouraged, along with any optional supplementary information e.g. relevant publications. Submissions should include the mechanism of action, biological rationale, a list of any validation work that has been completed, and patents that have been filed. In submitting to this campaign, you confirm that your submission contains only non-confidential information.

### Opportunity for Partnership

Our client is open to a range of partnership opportunities, with the most appropriate structure being decided on a case-by-case basis. Example outcomes include asset acquisition and in-licensing assets, although more collaborative models are also a potential opportunity.

## Opportunities sought

-  Technologies
-  Research projects
-  Biotech assets

## Submissions

Please submit relevant, non-confidential opportunities online [here](#)

Deadline: **7th April 2026 - 10:59 pm GMT**

### Have any questions?

Contact our team at [campaigns@inpart.io](mailto:campaigns@inpart.io)